Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from panax or acanthopanax
Reexamination Certificate
2001-09-12
2003-01-07
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from panax or acanthopanax
C424S725000, C424S757000, C424S764000, C424S773000, C424S774000
Reexamination Certificate
active
06503542
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel medicinal herbal composition and its use for treating patients with immunological disorders, particularly IgE mediated diseases, which include, but are not limited to, allergic rhinitis, allergic conjunctivitis, allergic asthma, atopic eczema, atopic dermatitis, food allergy, hyper IgE syndrome, and rheumatoid arthritis. The novel medicinal herbal composition contains aqueous extracts of
Tuber ophiopogon, Tuber pinelliae, Radix glycyrrhizae, Herba tridacis procumbentis,
and
Radix pancis quinquefolii.
The present invention also relates to a method for making the medicinal herbal composition and methods for treating patients with the medicinal herbal composition.
BACKGROUND OF THE INVENTION
Antigen-induced, particularly allergen-induced immunological disorders, such as asthma, has long been known as one of the serious health problems in the world. Allergy in one form or another afflicts more than 20% of the world population. In recent years, statistics shows that the onset of the allergic-related immunological disorders has shifted to the younger population, which means that more children and/or adolescents have developed symptoms of allergen-induced immunological disorders. For instance, in Taiwan, the prevalence of childhood asthma increased from 1.3% in 1974, to 5.07% in 1985, and to 5.8% in 1991. Also, allergic rhinitis increased from 7.84% in 1985 to 20.67% in 1991. Furthermore, atopic eczema was 1.43% in 1974 and 1.23% in 1985, in 1991, it was 3.84%. It is believed that the early onset of allergen-related immunological disorders are likely due to environmental pollution.
Respiratory allergies are immunoglobulin E (IgE)-mediated immune response. (See Brinker,
J. Naturopathic Medicine
, (1993):4:64-68). There are two major types of respiratory allergic reactions: The immediate hypersensitivity reactions include allergic rhinitis (hay fever) and allergic (extrinsic) bronchial asthma. Allergic rhinitis is brought on by antigen/IgE binding to sensitized mast cells and basophils, causing a decrease in cAMP which leads to release of esosinophil chemotactic factor and histamine. Histamine binding to H1-receptors has several results. It increases vasodilation, capillary permeability, and smooth muscle contraction, manifesting as nasal congestion with watery discharge, sneezing, and itching eyes.
Allergic asthma is another IgE-mediated immune response in which mast cells release histamine, bradykinin, and arachidonic acid metabolites including the leukotriene slow reacting substances of anaphylaxis and thromboxane/ prostaglandin bronchoconstrictors. Platelet activating factor is another potent asthma mediator released from a number of leukocytes. In this condition, histamine, which released after a decrease in cAMP, acts on H1-receptors to cause bronchospasm. It is also responsible for bronchoconstriction due to cholinergic reflex action and half of the prostaglandin generation in anaphylaxis.
While the percentage of affected population and severity of the diseases are rising, current methods for treating allergy still primarily depend on empirical and serendipitous findings rather than from scientific approach. At present, most patients are treated with drugs that aim at controlling symptoms resulted from the release of mediators by effector cells. Although some drugs appear to be effective in short term and with few occurrences of adverse effects, long term effects for preventing disease progression and permanent destruction are still largely unknown. For example, long-term oral therapy, such as steroid therapy, for treating asthma, is now known to be associated with multiple debilitating effects such as growth delay, osteoporosis, and adrenal suppression.
Traditional Chinese herbs and medicinal combinations have been known for improving function of immune system and treating various chronicle immunological disorders. For example, Hamasaki et al.,
J. Ethnopharmacology
, (1997) 56:123-131, disclose a Chinese herbal medicine, Shinpi-To, which inhibits IgE-mediated leukotriene synthesis in rat basophilic leukemia-2H3 cells. Shinpi-To is a freeze-dried granular Chinese herbal medicine prepared from extract of seven (7) medicinal herbs, i.e.,
Ephedrae herba
(
Ephedra sinica
Stapf),
Armeniacae semen
(
Prunus armeniaca
Linne),
Magnoliae cortex
(
Magnolia obovata
Thunberg),
Aurantii nobilis
Pericarpium (
Citrus unshiu
Markovich),
Glycyrrhizae radix
(
Glycyrrhiza uvalensis
Fischer),
Bupleuri radix
(
Bupleurum falcatum
L.), and
Perillae herba
(
Perilla frutescens
Britton var. acuta Kudo). Shinpi-To is useful for treating childhood asthma.
Toda et al.,
J. Ethnopharinacology
, (1988) 24:303-309, discloses a Chinese herbal medicine, Saiboku-To, which shows inhibitory effects on histamine release from mouse peritoneal mast cells. Saiboku-To is useful for treatment of asthma. Saiboku-To contains ten medicinal herbs:
Bupleurum falcatum
L.,
Pinellia ternata
Breitenbach,
Poria cocos
Wolf,
Scutellaria baicalensis
Georgi,
Zizyphus vulgaris
Lam.,
Panax ginseng
C. A. Meyer,
Magnolia oborata
Thumberg,
Glycyrrhiza glabra
L.,
Perilllae frutescens
Britton var. acuta Kudo, and
Zingiber officinale
Roscoe.
Li et al.,
Immunopharmacology
, (1999), 43:11-21, discloses a Chinese herbal medicine, Hochu-Ekki-To, which shows effects on restoring stress-induced immunosuppression. Hochu-Ekki-To consists often (10) ingredients, i.e., Ginseng Rx., Atractylodis alba Rz., Astragali Rx.,
Angelicae sinensis
Rx., Jujubae Fr.,
Citri reticulatae
Pc., Bupleuri Rx., Glycyrrhizae Rx. Preparata,
Zingiberis recens
Rz., and Cimicifugae Rz.
Zou et al.,
Chinese Traditional and Western Medical Magazine
, (1996):529-532, discloses a Chinese herbal medicine, Wenyang Tongluo mixture, for treating cold-type asthma patients. It shows effects on improving pulmonary ventilation functions, regulating adrenergic &bgr;-receptors of peripheral blood lymphocytes, and decreasing the serum level of 5-hydroxytryptamine. Wenyang Tongluo mixture contains twelve (12) medicinal herbs, i.e., Red Ginseng, Zhi Fu Pian, Yin Yang Huo, Dried Ginger (
Zingiberis recens
Rz.), Zhi Huang Zhi,
Angelicae sinesis
Rx., Ephedra, Polygalae Rx., Sang Baipi, Sheng Shi Gao, Schisandrae Fr., and Licorice (Glycyrrhizae Rx. Preparata).
There is also an ophiopogon decoction disclosed on the internet (www.herb.com.tw) which shows a combination of six (6) herbs, i.e., Ophiopogonis Rx., Pinelliae Rz. Preparata, Oryzae Sm., Jujubae Fr., Ginseng Rx., and Glycyrrhizae Rx. It is useful for treating bronchitis and bronchial asthma.
In dealing with Chinese herbal medicine, it is critical to control the quality of the herbs, because the contents and/or active ingredients of the herbs can vary significantly due to herb's growing conditions and harvesting seasons/techniques. If any of the critical conditions and factors, such as the locality where the herbs are grown, the season(s) when the herbs can be harvested, and the manufacturing process of the herb, are not met, the effectiveness of the herbal medicine would vary. So far, there has been no report showing the adoption of any reliable scientific method for monitoring the quality of the Chinese herbal medicine.
The present invention provides novel and non-toxic pharmaceutical compositions derived from herbs, which are primarily found in China and Taiwan. The combined use of these herbs has never been found in any literatures or reports. These pharmaceutical compositions are particularly effective in treating patients with immunological disorders, especially IgE mediated diseases. The pharmaceutical compositions of the present invention have demonstrated special effects on down-regulation of the synthesis of interleukin 4 (IL-4) and suppression of IgE. In addition, to effectively control the quality of the herbs, the present invention fingerprints each herb using thin layer chromatography (TLC) and high performance liquid chromatography (HPLC) to ensure that each herb used in the composition contains consiste
Chao Fei-Fei
GloboAsia L.L.C.
Lilling Herbert J.
Venable Baetjer Howard & Civiletti LLP
LandOfFree
Herbal compositions for treating immunological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herbal compositions for treating immunological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herbal compositions for treating immunological disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3035479